Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Investor	Date	% Owned	Market Value	Shares	Chg. Shares	Chg. Shares %	% Portfolio
Beech Tree S.A	2025-10-10	26.56546%	€2.55B	21.8M	—	—	—
Anne Beaufour	2025-10-10	26.56546%	€2.55B	21.8M	—	—	—
Parvus Asset Management Jersey Limited	2025-03-31	6.93736%	€664.87M	5.7M	—	—	7.4%
Finhestia	2025-10-10	4.67129%	€447.69M	3.8M	—	—	—
MR Schwabe	2024-12-31	4.42799%	€424.37M	3.6M	—	—	—
BlackRock, Inc.
The Vanguard Group, Inc.
Government Pension Fund Global
Norges Bank Investment Management
ODDO BHF Asset Management SAS
Vanguard STAR Funds - Vanguard Total International Stock ETF
Dimensional Fund Advisors LP
Liontrust Asset Management PLC
Liontrust European Dynamic Fund
Geode Capital Management, LLC
Amundi Asset Management SAS
Vanguard Tax-Managed Funds - Vanguard FTSE Developed Markets ETF
Boston Partners Global Investors, Inc.
Black Creek Investment Management Inc.
Vanguard Fiduciary Trust Company Institutional Total International Stock Market Index Trust II

Ipsen S.A.

Top Holders